English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA Cleveland Clinic research team has published the first study assessing the independent real-world impacts of weight loss and blood sugar control on clinical outcomes in people with type 2 diabetes treated with antidiabetic medications, and specifically with GLP-1RAs (the…
Tag: GLP-1 RAs
Nutrition know-how for patients taking anti-obesity medication
Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they’re a magic bullet for better health, and it doesn’t necessarily matter what you eat when you’re taking them. Nothing could be further from the truth.
Modification of Common Diabetes Drug Improved Blood Sugar Control in Mouse Model
Article title: Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice Authors: Rathin Bauri, Shilpak Bele, Jhansi Edelli, Neelesh C. Reddy, Sreenivasulu Kurukuti, Tom Devasia, Ahamed Ibrahim, Vishal Rai, Prasenjit Mitra From the authors: “Chronic…
UNC Health Researchers Present Preliminary Data on Weight Loss Drugs on Alcohol Addiction
Christian Hendershot, PhD, associate professor of psychiatry and director of the Clinical and Translational Addiction Research Program at the UNC School of Medicine, presented early findings from the first completed randomized controlled trial of semaglutide for reducing alcohol consumption in heavy drinkers.
Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns
Studies from multiple UChicago experts show that while GLP-1RA drugs are extremely effective for weight loss and Type 2 diabetes treatment, there’s no one-size-fits-all solution and physicians and patients have to consider issues like cost and side effects.
Weight loss and diabetes management drug linked to increased residual gastric content before anesthesia
Safety concerns for patients undergoing anesthesia who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are medications approved for diabetes and weight management, were revealed in a UTHealth Houston study published today in JAMA Surgery.